Abstract 18381: Safety of Echocardiographic Contrast in Patients With Pulmonary Hypertension
Background: Echocardiographic contrast (EC) improves the diagnostic accuracy of suboptimal echocardiographic studies. Limited data is available regarding the safety of EC in patients with pulmonary hypertension. We aimed to evaluate the safety of the EC agent Definity in patients with pulmonary hypertension.
Methods: We analyzed consecutive patients with pulmonary hypertension, who were referred for echocardiographic evaluation, but required the use of EC. We evaluated these patients for serious adverse events (respiratory decompensation, hypotension, loss of consciousness, convulsions, arrhythmias, death) occurring within 24 hours of EC administration.
Results: Our cohort included 552 patients (age 66±14 years, 44% males). A total of 305 (55%) patients had transthoracic echocardiograms, 244 patients (44.5%) had stress echocardiograms and 3 (0.5%) patients had transesophageal echocardiograms. The indications for EC use were LV opacification and endocardial border delineation (98%), evaluation of LV or left atrial appendage thrombus (0.5%) and Doppler signal enhancement (1.5%). Three hundred and forty(61%) patients had mild pulmonary hypertension, 169 (31%) had moderate pulmonary hypertension and 43 (8%) had severe pulmonary hypertension. The mean pulmonary artery systolic pressure in the groups with mild, moderate and severe pulmonary hypertension were 41±3 (range 35–49) mm Hg, 55±5 (range 50–69) mm Hg and 76±8 (range 70–100) mm Hg, respectively (Table). Only one patient in the mild pulmonary hypertension group had an episode of nonsustained ventricular tachycardia during peak dose of dobutamine stress echo, which was attributed to inducible ischemia.
Conclusion: The use of EC is safe in patients with pulmonary hypertension.
- © 2010 by American Heart Association, Inc.